SYSMEX CORPORATION

The Group’s principal business is the development, manufacture, sale, servicing, import and export of laboratory testing instruments and reagents for the medical field. In addition to laboratory testing instruments and reagents, it provides solutions to address the challenges faced by medical institutions by combining software, maintenance services for laboratory testing instruments, academic support and other services. The Group has 80 consolidated subsidiaries and 2 affiliated companies and other entities in Japan and overseas, and operates through the following regional headquarters: Headquarters, the Americas, EMEA, China and AP. Its product portfolio comprises instruments, reagents, maintenance services and other products and services, which it offers in Japan and overseas. Its long-term vision is “Together for a better healthcare journey.” The Group is pursuing Long-Term Management Plan 2033 (VA33), which runs through fiscal 2033. As part of its sustainability management initiatives, it has formulated Sysmex Eco-Vision 2033 and is promoting efforts to reduce its environmental impact, circulate resources and expand green procurement. The four themes of the medium-term management plan launched in April 2026 are strengthening the competitiveness of the diagnostics business, promoting healthcare DX and the use of data, improving profitability through value chain transformation, and redesigning its financial and capital strategy. Based on its global business expansion, the Group aims to improve capital efficiency by achieving an ROE of 12.0% in fiscal 2028, and plans to enhance shareholder returns through progressive dividends and share repurchases, targeting a dividend payout ratio of approximately 40%.